 |
 |
Oxford BioMedica Announces Six-Month Efficacy Results With Low Dose of ProSavin in Phase I/II Trial in Parkinson’s Disease - Improvements in Motor Function Maintained at Six Months - http://www.pharmalive.com/News/index.cfm?articleid=586610&categoryid=40 ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn